The first dose of COVID‐19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?

During the COVID-19 pandemics the management of immunosuppressed patients, such as those affected by autoimmune bullous diseases (AIBDs), became a matter of particular concern for healthcare systems; dissemination of sound and updated information became mandatory to orient physicians and, more generally healthcare policy [1,2]. Furthermore, AIBDs patients were encouraged take advantage from teledermatological rather than in-person consultations; also, they were encouraged to undergo COVID-19 vaccination, preferably during remission periods or at least while under low immunosuppression [3,4].